Skip to content
DataLookout
Menu

RESOLVENCT05608681

A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words
    • Trial sites expanded: 23 → 33 locations
    • Secondary endpoints: details revised at 16 of 19 entries
  2. Minor Study sites: 19 to 23v11
  3. Notable Primary endpoints revised (6)
    • Study sites: 7 to 19
    • Secondary endpoints revised (19)
    v10
  4. Notable Enrollment target: 57 to 117v9 Show 8 more changesShow less
    • Primary and study completion dates: Dec 2025 to Dec 2026
    • Eligibility criteria expanded, about 65 words
    • Primary endpoints revised (6)
    • Study sites: 5 to 7
    • Interventions: EP-104IAR (Drug) to EP-104GI (Drug), Matching vehicle control (Other)
    • Secondary endpoints: 28 to 19
    • Study title revised
    • Study arms: 9 to 12
  5. Notable Enrollment target: 24 to 57v8 Show 5 more changesShow less
    • Primary and study completion dates: Nov 2024 to Dec 2025
    • Primary endpoints: 4 to 6
    • Secondary endpoints: 16 to 28
    • Site details revised at 2 of 5 sites
    • Study arms: 8 to 9
Show 6 earlier versionsHide 6 earlier versions
  1. Notable Phase: Phase 1 to Phase 1/2
    • Study title expanded, about 2 words
    v7
  2. Minor Study sites: 4 to 5v6
  3. Notable Primary and study completion dates: Sep 2023 to Nov 2024v5
  4. Minor Site details revised at 1 of 4 sitesv4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 4
    • Start date changed from estimate of Jan 2023 to Mar 31, 2023
    v3
  6. Notable Start date: Nov 2022 to Jan 2023v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose Escalation- Incidence of treatment emergent adverse events (TEAEs)
Timeframe: 52 weeks
Dose Escalation- Severity of treatment emergent adverse events (TEAEs)
Timeframe: 52 weeks
Dose Escalation- Change from baseline in morning serum cortisol levels
Timeframe: 52 weeks
Dose Escalation- Plasma concentrations of fluticasone propionate
Timeframe: 108 weeks
Dose Escalation- Change from baseline in physical examination results, BMI and weight change.
Timeframe: 12 weeks
Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)
Timeframe: 24 weeks

Secondary (19)

Dose Escalation- Peak eosinophil count (PEC)
Dose Escalation- Change from baseline in the Straumann Dysphagia Index (SDI) score
Dose Escalation- Change from baseline in dysphagia measured on an 11 point Likert scale
Dose Escalation- Change from baseline in the EoE Endoscopic Reference Score (EREFS)
Dose Escalation- Change from baseline in odynophagia measured on an 11 point Likert scale
Show 14 moreShow less
Dose Escalation- Change from baseline in EoE Histology Scoring System (EoEHSS) score
Randomised Dose Optimization- Change from baseline in the Straumann Dysphagia Index (SDI) score
Randomised Dose Optimization- Change from baseline in the Dysphagia symptom questionnaire (DSQ) v4.0 and "Dysphagia days"
Randomised Dose Optimization- Change from baseline in the Eosinophilic Esophagitis Impact Questionnaire (EoE IQ)
Randomised Dose Optimization- Change from baseline in the Patient Global Impression of Change (PGIC)
Randomised Dose Optimization- Change from baseline in the Patient Global Impression of Severity (PGIS)
Randomised Dose Optimization- Change from baseline in peak eosinophil count (PEC)
Randomised Dose Optimization- Change from baseline in the EoE Endoscopic Reference Score (EREFS) in 3 regions of the esophagus within the injection area (proximal, mid, distal)
Randomised Dose Optimization- Change in endoscopist's global impression of severity
Randomised Dose Optimization- Change from baseline in EoE Histology Scoring System (EoEHSS) score in 3 regions of the esophagus within the injection area (proximal, mid, distal), excluding Week 24 as this is the primary endpoint
Randomised Dose Optimization- Change from baseline in morning serum cortisol levels
Randomised Dose Optimization- Change from baseline in vital signs (temperature, blood pressure, pulse, and respiratory rate) results
Randomised Dose Optimization- Change from baseline in physical examination results, BMI and weight change.
Randomised Dose Optimization- Plasma concentrations of fluticasone propionate

Arms and interventions

EP-104GI 4 mgExperimental

4 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 8 mgExperimental

8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 20 mgExperimental

8 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 30 mgExperimental

12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 48 mgExperimental

12 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 64 mgExperimental

16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 80 mgExperimental

20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 96 mgExperimental

16 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 120 mgExperimental

20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI Dose A or matching vehicle controlPlacebo comparator

20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI 160 mgExperimental

20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

EP-104GI Dose B or matching vehicle controlPlacebo comparator

20 submucosal injections of EP-104GI administered during an EGD procedure at the Baseline/Dosing visit.

Drugs: EP-104GI

Other: Matching vehicle control

Sites

33 sites in 6 countries

Australia 12, Canada 9, United Kingdom 6, New Zealand 3, Netherlands 2, Switzerland 1